The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.

Qiagen (QGEN) announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a provider of scalable, instrument-free ...